JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266327

Human SLC25A22 (GC-1) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SLC25A22 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)

Allele-1 : 8 bp deletion in exon 3

Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)
  • Sanger seq

Lab

Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)

Sequencing chromatogram displaying sequence edit in exon 3

Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC25A22 (GC-1) knockout HEK-293T cell line (AB266327)

Allele-2 : 1 bp insertion in exon 3.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266327-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266327-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266327 Human SLC25A22 (GC-1) knockout HEK-293T cell line", "number":"AB266327-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266327-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266327-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266327 Human SLC25A22 (GC-1) knockout HEK-293T cell line", "number":"AB266327-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266327-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266327 Human SLC25A22 (GC-1) knockout HEK-293T cell line", "number":"AB266327-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266327-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266327 Human SLC25A22 (GC-1) knockout HEK-293T cell line", "number":"AB266327-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SLC25A22
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GC-1 also known as guanylate cyclase 1 is an enzyme with an approximate molecular mass of 82 kDa. It functions mechanically by converting GTP to cGMP a critical second messenger in various cellular processes. GC-1 is expressed in a range of tissues including the brain and retina where it plays important roles in visual and neural functions. Its distribution indicates its involvement in both sensory perception and broader neurological activities.
Biological function summary

GC-1 plays an important role in the signal transduction pathways involving nitric oxide as part of a complex with protein partners. As a subunit of the soluble guanylate cyclase (sGC) complex it helps mediate the effects of nitric oxide by regulating cGMP levels. This activity is essential for promoting vasodilation and blood flow which is observed in the cardiovascular system. The GC-1 complex translates extracellular signals to intracellular responses affecting various physiological processes.

Pathways

GC-1 is a critical component in the nitric oxide signaling pathway where it facilitates communication between nitric oxide and cGMP-dependent pathways. It interacts closely with proteins such as endothelial nitric oxide synthase (eNOS) and is directly involved in the pathway regulating vascular tone and blood pressure. Additionally GC-1 is part of the phototransduction pathway in retinal cells influencing the conversion of light into electrical signals through its production of cGMP.

GC-1 has significant implications in cardiovascular diseases and certain eye disorders. For cardiovascular diseases GC-1 contributes to conditions related to hypertension and heart failure as it affects the nitric oxide-cGMP pathway's ability to mediate vascular relaxation. In the realm of eye disorders particularly retinitis pigmentosa impaired GC-1 function affects photoreceptor cells and visual signal transduction. GC-1's activity is linked to proteins like phosphodiesterase 6 (PDE6) which further highlights its role in maintaining visual acuity and retinal health.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com